EUVIMEDEUVIMED entdecken
Open Access

Dose‐escalation trial of combination dabrafenib, trametinib, and AT13387 in patients with BRAF ‐mutant solid tumors

Meghan J Mooradian iD, James M Cleary, Anita Giobbie-Hurder, Lancia N F Darville, Aparna Parikh iD, Elizabeth I Buchbinder iD, Justine V Cohen iD, Donald P Lawrence, Geoffrey I Shapiro, Harold Keer, Helen X Chen, Susan Percy Ivy iD und 3 weitere

Cancer · 2023

DOI: 10.1002/cncr.34730 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer, 2023. Verfasst von Meghan J Mooradian und 14 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Melanoma, Colorectal Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Combination BRAF and MEK inhibitor therapy is an active regimen in patients who have BRAF V600E ‐mutated tumors; however, the clinical efficacy of this therapy is limited by resistance. Preclinically, the addition of heat shock protein 90 (HSP90) inhibition improves the efficacy of BRAF inhibitor therapy in both BRAF inhibitor–sensitive and BRAF inhibitor–resistant mutant cell lines.

Methods

Cancer Therapy Evaluation Program study 9557 (ClinicalTrials.gov identifier NCT02097225) is a phase 1 study that was designed to assess the safety and efficacy of the small‐molecule HSP90 inhibitor, AT13387, in combination with dabrafenib and trametinib in BRAF V600E/K –mutant solid tumors. Correlative analyses evaluated the expression of HSP90 client proteins and chaperones.

Results

Twenty‐two patients with metastatic, BRAF V600E –mutant solid tumors were enrolled using a 3 + 3 design at four dose levels, and 21 patients were evaluable for efficacy assessment. The most common tumor type was colorectal cancer ( N = 12). Dose‐limiting toxicities occurred in one patient at dose level 3 and in one patient at dose level 4; specifically, myelosuppression and fatigue, respectively. The maximum tolerated dose was oral dabafenib 150 mg twice daily, oral trametinib 2 mg once daily, and intravenous AT13387 260 mg/m 2 on days 1, 8, and 15. The best response was a partial response in two patients and stable disease in eight patients, with an overall response rate of 9.5% (90% exact confidence interval [CI], 2%–27%), a disease control rate of 47.6% (90% CI, 29%–67%), and a median overall survival of 5.1 months (90% CI, 3.4–7.6 months). There were no consistent proteomic changes associated with response or resistance, although responders did have reductions in BRAF expression, and epidermal growth factor receptor downregulation using HSP90 inhibition was observed in one patient who had colorectal cancer.

Conclusions

HSP90 inhibition combined with BRAF/MEK inhibition was safe and produced evidence of modest disease control in a heavily pretreated population. Additional translational work may identify tumor types and resistance mechanisms that are most sensitive to this approach.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaColorectal NeoplasmsHumansProto-Oncogene Proteins B-rafProteomicsPyridonesPyrimidinonesOximesProtein Kinase InhibitorsMitogen-Activated Protein Kinase KinasesMutationAntineoplastic Combined Chemotherapy ProtocolsBenzamidesIsoindolesImidazoles

Stichwörter der Autor:innen

BRAF inhibitorBRAF-mutantMEK inhibitorheat shock protein 90 (HSP90) inhibition

Substanzen

Proto-Oncogene Proteins B-rafPyridonesPyrimidinonesOximesProtein Kinase InhibitorsMitogen-Activated Protein Kinase Kinases(2,4-dihydroxy-5-isopropylphenyl)-(5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl)methanoneBenzamidesIsoindolestrametinib

Autor:innen und Institutionen

  • Division of Medical Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Harvard Medical School, Boston, Massachusetts, USA.
  • Division of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Division of Biostatistics, Departments of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Department of Proteomics and Metabolomics Core, Moffitt Cancer Center, Tampa, Florida, USA.
  • Astex Pharmaceuticals Inc., Pleasanton, California, USA.

ORCID-Profile: Meghan J Mooradian, Aparna Parikh, Elizabeth I Buchbinder, Justine V Cohen, Susan Percy Ivy, Ryan J Sullivan

Förderung

  • NCI NIH HHS

Zitieren

APA

Mooradian, M. J., Cleary, J. M., Giobbie-Hurder, A., Darville, L. N. F., Parikh, A., Buchbinder, E. I., Cohen, J. V., Lawrence, D. P., Shapiro, G. I., Keer, H., Chen, H. X., Ivy, S. P., Smalley, K. S. M., Koomen, J. M., & Sullivan, R. J. (2023). Dose‐escalation trial of combination dabrafenib, trametinib, and AT13387 in patients with BRAF ‐mutant solid tumors. Cancer. https://doi.org/10.1002/cncr.34730

Vancouver

Mooradian MJ, Cleary JM, Giobbie-Hurder A, Darville LNF, Parikh A, Buchbinder EI, et al. Dose‐escalation trial of combination dabrafenib, trametinib, and AT13387 in patients with BRAF ‐mutant solid tumors. Cancer. 2023. doi:10.1002/cncr.34730

BibTeX
@article{Mooradian2023,
  author = {Mooradian, Meghan J and Cleary, James M and Giobbie-Hurder, Anita and Darville, Lancia N F and Parikh, Aparna and Buchbinder, Elizabeth I and Cohen, Justine V and Lawrence, Donald P and Shapiro, Geoffrey I and Keer, Harold and Chen, Helen X and Ivy, Susan Percy and Smalley, Keiran S M and Koomen, John M and Sullivan, Ryan J},
  title = {Dose‐escalation trial of combination dabrafenib, trametinib, and AT13387 in patients with BRAF ‐mutant solid tumors},
  journal = {Cancer},
  year = {2023},
  doi = {10.1002/cncr.34730}
}
Kostenlos starten →